Complete cure of HBV-HDV co-infection after 24weeks of combination therapy with pegylated interferon and ribavirin in a patient co-infected with HBV/HCV/HDV/HIV  by Gozlan, Joel et al.
www.elsevier.com/locate/jhep
Journal of Hepatology 50 (2009) 432–434Case report
Complete cure of HBV-HDV co-infection after 24 weeks
of combination therapy with pegylated interferon and ribavirin
in a patient co-infected with HBV/HCV/HDV/HIVq
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6Universite´ Pierre et Marie Curie, Paris, FranceMultiple hepatitis co-infections are frequent in HIV-infected patients, often resulting in severe liver diseases that are
diﬃcult to treat. We report here the complete resolution of a chronic hepatitis B and D co-infection in a patient who
was also infected with HCV and HIV. This cure was observed after 24 weeks of combination therapy associating pegy-
lated-IFN and ribavirin, which was initially given to treat HCV. An unexpected and extensive HDV replication was
observed in this patient after HBs Ag had cleared from the serum, which was followed by a stable halt in HDV replication.
Implications of this unusual observation will be discussed.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Chronic HBV–HDV co-infection usually results in
severe and rapidly progressive liver disease, which is dif-
ﬁcult to treat. Interferon-a (IFN) is the only approved
treatment against such co-infections and must be admin-0168-8278/$34.00  2008 European Association for the Study of the Liver.
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combined antiretroviral therapy.istered at high doses for a prolonged period of time if a
long-term response is to be achieved [1]. Clinical trials
evaluating pegylated interferon-a (peg-IFN) in HBV–
HDV co-infected patients have recently demonstrated
promising, but conﬂicting results [2–4]. We describe here
the complete resolution of HBV–HDV co-infection in a
patient also infected with HCV and HIV, after a 24-
week course of peg-IFN and ribavirin (RBV). Surpris-
ingly, a transient but extensive HDV replication
occurred in this patient after HBsAg seroconversion,
followed by a stable halt in HDV replication.
2. Case report
A 44-year-old man presented with positive HIV-1
serology at ﬁrst observation in March 1996. He had qua-
druple infection with positive HBsAg, anti-HCV, and
total anti-HDV antibodies. HCV RNA (genotype 1)Published by Elsevier B.V. All rights reserved.
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IgM anti-HDV were found. Initial biochemical liver tests
were normal. Because of a high HIV viral load (VL) and
a low CD4 cell count, combined antiretroviral therapy
(cART) with stavudine, lamivudine and indinavir was
immediately initiated. This therapy was successful in rap-
idly reducing the HIV viral load and increasing the CD4
cell count. HIV-1 infection remained controlled under
ART, which consistently included lamivudine. Hepatic
tests remained within the normal range until February
2001 at which time liver enzymes signiﬁcantly increased
(Fig. 1). A liver biopsy performed in April 2001 indicated
a Metavir score of A2 F1. HBsAg was still detectable at
this time (October 2001), but the HBV viral load was
below 125,000 IU/ml (sensitivity threshold of the
branched DNA assay used) and HBeAg was undetect-
able. HDV RNA quantiﬁcation was not available at that
time. Liver enzymes ﬂuctuated after that, reaching the
highest levels between September 2001 and February
2002. In consideration of the signiﬁcant aminotransfer-
ase ﬂare, a combination therapy with PEG-IFN a2b
(120 lg per week) and RBV (1000 mg per day) was
started in April 2002, during which time the ART regi-
men comprised lamivudine, stavudine and efavirenz.
Baseline HCV RNA was over 3  106 IU/ml and was
still detectable after 24 weeks of treatment (45,700 IU/Fig. 1. Evolution of biological and virological parameters before, during and af
(RBV). Alanine aminotransferase (ALT) and aspartate aminotransferase (A
are also provided, expressed in international units per ml. HBs antigen
displayed at the top of the ﬁgure, as well as the results of HBV DNA and HDml) when both PEG-IFN and RBV were discontinued
due to poor tolerability. However, the interrupted anti-
HCV therapy had an unexpected eﬀect on HBV infection
resulting in HBsAg clearance in October 2002. A sensi-
tive PCR assay (HBV Cobas Monitor Roche Diagnostic,
sensitivity: 60 IU per ml) showed negative serum HBV
DNA. Moreover, the patient seroconverted to anti-
HBs (15 mIU/ml), suggesting cure of HBV infection.
HBsAg clearance was surprisingly associated with a high
level of HDV replication, with HDV RNA levels of
9.3  106 copies/ml by real time PCR [5]. This peak of
HDV replication was transient as HDV infection
resolved after HBV, with clearance of serum HDV
RNA 6 months later (tested with the same PCR assay,
sensitivity: 100 copies/ml). This proﬁle of dual cure of
HBV and HDV persisted over time, and was accompa-
nied by an increase in anti-HBs titre (>150 mIU/ml on
October 2003); HBsAg, HBV DNA, and HDV RNA
had also been negative in serum every year since 2003.
No further treatment for HCV infection was attempted.
At present the patient is doing well and his HIV infection
is currently under control with abacavir, lamivudine and
efavirenz. Biochemical markers of liver functions have
remained persistently normal, whereas transient elas-
tometry indicated a liver stiﬀness of 7.8 kPa, suggesting
the presence of moderate ﬁbrosis.ter the administration of pegylated interferon a (peg-IFN) and Ribavirin
ST) levels are shown in the graph. Levels of HCV RNA viral load
and antibody detection or quantiﬁcation (expressed in mIU per ml) are
V RNA detection (expressed in IU and copies per ml, respectively).
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Two main ﬁndings are remarkable in this case report.
The ﬁrst is that a sustained resolution of HBV-HDV co-
infection was observed after only 6 months of PEG-IFN
and RBV. Although pilot studies have suggested that
PEG-IFN may increase the rate of anti-HDV response
[2–4], complete responses are still anecdotal and patients
require prolonged exposure to therapy. No cure of
HBV-HDV infection under PEG-IFN has ever been
described in HIV-HBV-HDV-HCV co-infected patients,
with the exception of a single case [6] in which treatment
with peg-IFN-a2b for 18 months resulted in HBV DNA
and HDV RNA clearance. However, neither HBsAg
clearance nor seroconversion to anti-HBs antibodies
had occurred. We believe that treatment success may
be due to the immune response developed by the patient
a few months before starting PEG-IFN, resulting in an
aminotransferase ﬂare. We feel that initiation of inter-
feron treatment was timely resulting in enhancement
of the immune response, thus positively aﬀecting HBV
resolution. The inhibitory eﬀects of HDV and/or HCV
on HBV replication [7,8] might be another factor that
facilitated the combined eﬀect of IFN and the immune
response. The contribution of lamivudine and/or RBV
to HBV-HDV resolution is unlikely since many studies
have shown no beneﬁt upon addition of these drugs to
IFN in patients with delta hepatitis [8,3,9]. The other
remarkable ﬁnding in this observation is the high
HDV replication observed after HBs Ag clearance from
serum. HBsAg is required for packaging, export and
spread of HDV particles to other cells. However, contin-
uous replication of HDV with the helper function of
HBV has been shown in a cell culture system, indicating
that replication of HDV genome itself is independent
from HBV [10]. In liver transplants for HBV-HDV have
related cirrhosis, HDV re-infection of the graft with sub-
sequent HDV viremia has been observed in the absence
of detectable HBV in the blood, raising the hypothesis
of an ‘‘autonomous” HDV infection occurring in vivo
[7]. The use of sensitive PCR-based assays for HBV
detection however challenged this hypothesis [11], sug-
gesting that these observations likely rely on a true dual
infection of hepatocytes, with very low levels of HBV
replication. In our opinion, a transient persistence of
HBV replication in co-infected hepatocytes, at the time
when HBsAg was no longer detectable in the blood,
may explain the isolated detection of HDV RNA.
Another hypothesis is the occurrence of a restricted,
HBV independent, replication of HDV RNA genome,
followed by the release of viral ribo-nucleoproteincaused by the immune-mediated destruction of infected
hepatocytes. Whatever the precise mechanism of this
unusual ﬁnding, this ‘‘isolated” HDV detection was
transient, in agreement with experiments performed in
a simian model [11].4. Conclusions
Our observation conﬁrms the potential eﬃcacy of
PEG-IFN a for HBV-HDV co-infection in a multiple
infection setting, especially if therapy is administered
at the time when spontaneous immune response has
started.
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